Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tovinontrine (Primary)
  • Indications Heart failure
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Cycle-1-REF
  • Sponsors Cardurion Pharmaceuticals; Enliven Therapeutics; Imara Inc

    • Most Recent Events

    • 16 Jul 2024 According to a Cardurion Pharmaceuticals media release, company announced it has raised a $260 million Series B financing led by Ascenta Capital and proceeds from the financing will be used to support later-stage clinical trials with the company's two lead drug candidates CRD-750 and CRD-4730.
    • 08 Mar 2024 Status changed from not yet recruiting to recruiting.
    • 23 Feb 2023 According to an Enliven Therapeutics media release, Imara Inc has merged with Enliven Therapeutics. The combined company will operate under the name, Enliven Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top